Given our optimal dose/minimal effective dose is yet to be authorised.
Given the drug is yet to be classified as a “pain and function” or “Dmoad” drug
Given ambiguity around phase 3 trial metrics
Given TGA may or may not authorise our early application
Given cautious global bio pharma market environment
Given our supplier may also hold some decision making power on partnerships
Given our dire financial situation
……. maybe, just maybe our “deal” potential is held up until some of these dominos fall one way or another.
I’m not for a second saying I’m right here, or that others are wrong. I think some of the slides from last Fridays slide deck are encouraging, though.
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-4261
-
-
- There are more pages in this discussion • 168 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.0¢ |
Change
-0.010(5.00%) |
Mkt cap ! $66.54M |
Open | High | Low | Value | Volume |
20.0¢ | 21.0¢ | 19.0¢ | $203.4K | 1.019M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 387930 | 19.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 65468 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 387930 | 0.190 |
3 | 57000 | 0.185 |
10 | 205428 | 0.180 |
6 | 140904 | 0.175 |
8 | 615605 | 0.170 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 65468 | 2 |
0.210 | 28079 | 4 |
0.215 | 30000 | 1 |
0.220 | 27066 | 4 |
0.225 | 21604 | 2 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |